|
TMLHE expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.5169000500137E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.39110000874877E-09 |
| Normal-vs-Stage2 |
2.062900E-03 |
| Normal-vs-Stage3 |
1.110699998641E-08 |
| Normal-vs-Stage4 |
2.7838000016267E-08 |
| Stage1-vs-Stage2 |
1.882030E-01 |
| Stage1-vs-Stage3 |
2.925000E-01 |
| Stage1-vs-Stage4 |
2.071600E-01 |
| Stage2-vs-Stage3 |
7.224100E-02 |
| Stage2-vs-Stage4 |
5.455600E-02 |
| Stage3-vs-Stage4 |
6.885600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.28229982188088E-10 |
| Normal-vs-AfricanAmerican |
8.793900E-02 |
| Normal-vs-Asian |
1.62770000000645E-06 |
| Caucasian-vs-AfricanAmerican |
9.918700E-03 |
| Caucasian-vs-Asian |
9.920200E-01 |
| AfricanAmerican-vs-Asian |
3.770400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.35770003520486E-09 |
| Normal-vs-Female |
1.39269999976932E-08 |
| Male-vs-Female |
1.963380E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.15990000329569E-08 |
| Normal-vs-Age(41-60Yrs) |
3.97980004507303E-09 |
| Normal-vs-Age(61-80Yrs) |
3.61020000000378E-05 |
| Normal-vs-Age(81-100Yrs) |
1.261430E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.555000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.428200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.930600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.833790E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.932600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.345200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.290800E-01 |
| Classical-VS-Follicular |
7.283800E-02 |
| Classical-VS-Other |
8.474200E-01 |
| Classical-VS-Normal |
4.57810012122195E-10 |
| Tall-VS-Follicular |
8.338500E-03 |
| Tall-VS-Other |
5.498400E-01 |
| Tall-VS-Normal |
6.12830000079612E-08 |
| Follicular-VS-Other |
4.828400E-01 |
| Follicular-VS-Normal |
1.055390E-03 |
| Other-VS-Normal |
1.032220E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.77139999838028E-08 |
| Normal-vs-N1 |
1.03230000103594E-08 |
| N0-vs-N1 |
8.110100E-02 |
|
|
